BioWorld looks at translational medicine, including: How the eye cleans itself up; In blood stem cells, selection drives driver mutations early on; Dead cells do tell tales; Selective TGF-beta inhibition helps checkpoint blockade; How lung tumors seed to brain; Butyrate affects regulatory B cells, rheumatoid arthritis; Lamin A/C’s presence in nucleus, absence from membrane both problematic in progeria; Females, males have different metabolic response to intermittent fasting; Ditching PAMs expands CRISPR.
Keeping you up to date on recent developments in diagnostics, including: Improving TBI prognosis; Speeding detection of antibiotic resistant infections; Multistep method wrests causality from GWAs; In blood stem cells, selection drives driver mutations early on.
Keeping you up to date on recent developments in oncology, including: New study hints that 3D chromatin architecture a key in childhood leukemia; Recruiting NK cells to the antitumor battle; 3D printing meets the medical isotope business.
Keeping you up to date on recent developments in neurology, including: ‘Natural killer’ cells could halt PD progression; Neuroinflammation linked to several forms of dementia; GOF, LOF mutations take different paths to same result; Study links GABA, mitochondria, social defects.
BioWorld looks at translational medicine, including: Heparan sulfate DAMPens acetaminophen toxicity; Study links GABA, mitochondria, social defects; Recruiting NK cells to the antitumor battle; Potassium channel blocker improves motor learning in fetal alcohol syndrome; A20s inflammation-fighting properties decoded; Brown fat activity without fat browning; Agonists selectively wake up melatonin receptor subtypes; Multistep method wrests causality from GWAS; BET on BD1 for cancer, BD2 for inflammation.
Keeping you up to date on recent developments in diagnostics, including: ‘Virtual peer review’ aids cancer diagnosis; Adding spirometry to lung cancer screenings to detect undiagnosed COPD; See in 3D; AI and sleep medicine.
The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results. In 200 hospitalized patients with severe COVID-19, a 14-day regimen of twice-daily treatment with Kaletra/Aluvia (lopinavir/ritonavir, Abbvie Inc.) did not hasten recovery when added to the standard of care.
Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
